跳至主要内容
临床试验/NCT00465855
NCT00465855已完成4 期

Randomized Trial of One Versus Three Hyperbaric Oxygen Treatments for Acute CO Poisoning

Intermountain Health Care, Inc.4 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2007年6月3日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
75
试验地点
4
主要终点
6-week cognitive sequelae

研究概览

简要总结

This randomized trial will investigate important clinical outcomes of patients with acute carbon monoxide poisoning randomized to receive either one or three hyperbaric oxygen treatments.

详细描述

All patients presenting with acute carbon monoxide poisoning will receive one hyperbaric oxygen treatment (barring contraindications for hyperbaric oxygen therapy). After this treatment, eligible patients who provide consent will be randomly allocated to receive two sham sessions, or two additional hyperbaric oxygen sessions administered in a double-blind fashion.

Outcome measures will be administered at 6 weeks and 6 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 79 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Symptomatic CO poisoning (headache, nausea, vomiting, dizziness, fatigue, muscle aches, slowed mentation, confusion, or loss of consciousness).
  • Carboxyhemoglobin (COHb) levels > 10% or confirmation of poisoning with ambient levels > 50 ppm in a patient with symptoms compatible with CO poisoning and no other reasonable explanation for their signs and symptoms.
  • Less than 24 hours from removal from the source of CO exposure and study enrollment.
  • Accidental poisoning

排除标准

  • Pregnancy
  • Age < 18 years or > 79 years
  • Complication during first hyperbaric oxygen session precluding subsequent hyperbaric oxygen.
  • Intentional CO poisoning
  • Unable to obtain informed consent
  • Moribund patient
  • Concomitant smoke inhalation with cyanide poisoning
  • Bleomycin use within two weeks of study enrollment
  • Intracardiac defibrillator that cannot be deactivated
  • Non-English speaking
  • Unlikely to return at 6 weeks
  • History of central nervous system (CNS) disease (i.e., Alzheimer's, Parkinson's, dementia, demyelinating disease (MS), etc.)
  • History of prior brain injury (i.e., stroke, traumatic brain injury)
  • Presence of chronic debilitating disease likely to result in death within 12 months (i.e., kidney failure on dialysis, heart failure)
  • Subject has a significant medical condition or conditions that would interfere with the treatment, safety, or compliance with the protocol.
  • Intubated subjects
  • Subjects requiring greater than 50% oxygen by non-rebreather facemask or exhibiting evidence of respiratory compromise or heart failure
  • Subjects who, in the opinion of the investigator, are unable to comply with the requirements of the study or are unsuitable for any reason. The investigator and the Sponsor, prior to enrolling the subject on a case-by-case basis, must approve and document any waiver of these inclusion and exclusion criteria.

结局指标

主要结局

6-week cognitive sequelae

时间窗: 6 weeks after poisoning

Presence of cognitive sequelae at 6-week follow-up

次要结局

  • Depression, anxiety or post-traumatic stress syndrome(6 weeks and 6 months after poisoning)
  • Vocational assessment(6 weeks and 6 months after poisoning)
  • Patient self-reports of CO-related problems(6 weeks and 6 months)
  • Neurological examination(6 weeks and 6 months after poisoning)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验